A phase II clinical study to assess efficacy and safety of AV-101 in patients suffering from neuropathic pain

Trial Profile

A phase II clinical study to assess efficacy and safety of AV-101 in patients suffering from neuropathic pain

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs AV 101 (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2018 According to a VistaGen Therapeutics media release, FDA authorization to initiate this trial is anticipated in the second half of 2018 and the trial is anticipated to initiate in the first half of 2019.
    • 19 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top